There are roughly 40 FDA-approved ADHD medications on the U.S. market, but they’re built from a much smaller number of active ingredients. Strip away the different brand names, release mechanisms, and delivery forms, and you’re looking at about 14 distinct drugs. The large number of products exists because the same core medication can be packaged as a pill, a patch, a liquid, a chewable tablet, or a capsule with different timed-release technology, and each version gets its own brand name.
Why the Count Is Confusing
Methylphenidate alone accounts for more than a dozen brand-name products. Concerta, Ritalin LA, Daytrana, Jornay PM, Quillivant XR, and Aptensio XR are all methylphenidate. The difference between them is how and when they deliver the drug into your system. Concerta uses an osmotic pump that pushes medication out gradually. Daytrana is a skin patch. Quillivant XR is a liquid. Jornay PM is designed to be taken at bedtime so it kicks in by morning. Each delivery method creates a different experience for the person taking it, even though the underlying molecule is the same.
The same pattern holds on the amphetamine side. Adderall, Vyvanse, Dexedrine, Mydayis, Dyanavel XR, and Xelstrym are all amphetamine-based, but they differ in their specific salt formulations, whether they’re immediate or extended release, and whether they come as pills, liquids, or patches.
The Two Main Categories
Every ADHD medication falls into one of two buckets: stimulants and non-stimulants. Stimulants are the first-line treatment for most people and make up the majority of available products. Non-stimulants are typically tried when stimulants cause intolerable side effects or don’t work well enough.
Stimulants
Stimulant medications increase the activity of dopamine and norepinephrine in the brain, which improves focus, impulse control, and the ability to stick with tasks. They split into two families based on their core ingredient:
- Methylphenidate-based: This family includes Ritalin, Concerta, Focalin, Focalin XR, Ritalin LA, Aptensio XR, Adhansia XR, Jornay PM, Daytrana (patch), Azstarys, Cotempla XR-ODT (dissolving tablet), Quillivant XR (liquid), and QuilliChew ER (chewable). Focalin and Azstarys use a refined version of methylphenidate that isolates the more active portion of the molecule.
- Amphetamine-based: This family includes Adderall and Adderall XR (mixed amphetamine salts), Vyvanse (a prodrug that your body converts into active amphetamine), Dexedrine, Zenzedi, ProCentra, Mydayis, Evekeo, Adzenys XR-ODT, Dyanavel XR, and Xelstrym (a patch). Desoxyn, a methamphetamine-based medication, is also FDA-approved but rarely prescribed.
Within each family, the main practical difference is duration of action. Immediate-release versions last about 4 hours and need to be taken two or three times a day. Extended-release versions last 8 to 16 hours depending on the product, which means one dose in the morning can cover the entire school or work day. Some newer formulations push even further: Mydayis is designed to last up to 16 hours, and Jornay PM shifts the entire timeline so the medication is active when you wake up.
Non-Stimulants
Four non-stimulant medications have clear FDA approval for ADHD:
- Atomoxetine (Strattera): Works by increasing norepinephrine availability in the brain. It takes several weeks to reach full effect, unlike stimulants which work within an hour.
- Viloxazine (Qelbree): A newer option that also targets norepinephrine. It was approved in 2021 for children and later expanded to adults.
- Guanfacine extended-release (Intuniv): Originally developed for blood pressure, it reduces hyperactivity and impulsivity by calming certain signaling pathways in the prefrontal cortex.
- Clonidine extended-release (Kapvay): Works similarly to guanfacine and is sometimes used alongside a stimulant to address symptoms the stimulant doesn’t fully cover.
Bupropion (Wellbutrin) is sometimes prescribed off-label for ADHD, particularly when someone also has depression, but it does not carry a formal FDA indication for ADHD.
Age Matters for Approval
Most FDA-approved ADHD medications have been tested and approved for children ages 6 and older. Some extended-release products are approved specifically for adults as well. The FDA has been pushing to include children as young as 4 and 5 in clinical trials, which could eventually expand the approved age range for some medications. For now, treating children under 6 often involves off-label prescribing, meaning the doctor is using a medication outside its formally approved age group.
Brand Name vs. Generic
Many of the older ADHD medications are available as generics, which can cost significantly less. Immediate-release methylphenidate and mixed amphetamine salts have been generic for years. Some extended-release products also have generic versions, though the story gets complicated. Not all generics for extended-release medications are rated as fully equivalent by the FDA. Certain generic versions of Concerta, for example, use different release mechanisms than the brand-name product, and the FDA has noted that available data on some of these generics are insufficient to confirm they perform identically. This is one reason some people notice a difference when switching between brand and generic for extended-release ADHD drugs.
Newer medications like Azstarys, Jornay PM, Qelbree, and Xelstrym are still under patent protection and don’t yet have generic alternatives. In 2025, the FDA approved a new oral solution form of lisdexamfetamine (the active ingredient in Vyvanse), giving people who have difficulty swallowing pills another option as Vyvanse generics have also become available.
How Doctors Narrow Down the Options
With so many products available, choosing a medication is less about picking from a list and more about matching a few key variables to your life. The first decision is usually stimulant vs. non-stimulant. If stimulants are appropriate, the next choice is methylphenidate-based or amphetamine-based. Roughly 70% of people respond well to the first stimulant family they try, and many of those who don’t will respond to the other family.
After that, the decision comes down to practical factors: how many hours of coverage you need, whether you can swallow pills, whether you want the option of a patch or liquid, and how you respond to immediate vs. gradual release profiles. Someone who needs all-day coverage at a demanding job has different needs than a college student who wants flexibility to take a short-acting dose only on study days. A child who can’t swallow capsules might do better with a chewable tablet or liquid.
The sheer number of formulations exists precisely because no single version works perfectly for everyone. Small differences in how quickly a drug enters your bloodstream, how long it lasts, and how it tapers off at the end of the day can make a real difference in side effects like appetite loss, sleep disruption, or the “crash” some people feel when a dose wears off. Finding the right fit often takes some trial and adjustment, but the variety of options means most people can land on something that works.